Three Brazilian health startups are getting a route into Lisbon. But the story is bigger than healthcare: the companies were selected as part of a 20-startup cohort for an international incubation programme, not a health-only award.
Sebrae and ApexBrasil announced the selection at Web Summit Lisbon's Brazil pavilion on November 10, 2026. The incubation cycle is scheduled to begin in March 2027, with workspace at ApexBrasil's Lisbon office available for up to nine months. The three clearly health-related companies named in the cohort are Agendart, MedHy (Smart Healthy) and Odapp.
What was announced at the Brazil pavilion?
Sebrae and ApexBrasil presented a programme intended to help selected Brazilian startups develop international connections from Lisbon. The group includes companies across different industries. Healthcare is one component, not the sole focus.
A seat in a programme is an opportunity, not evidence that a company has entered the European market. Participants still need to establish customer relationships, adapt their offerings and meet relevant requirements.
Which Brazilian health startups were selected?
Agendart is one of the health-oriented names in the official cohort. Its inclusion reflects its participation in the programme; it does not, by itself, demonstrate a new European contract or a healthcare-system deployment.
MedHy, also identified as Smart Healthy, is among the health-related companies selected for the Lisbon incubation cycle.
Odapp completes the trio of health-related companies named in the selection, alongside Agendart and MedHy.
Product categories shape who might buy a technology, how it would fit into care and which professional or regulatory requirements apply. The selected companies will need market-specific use cases as they develop their expansion plans.
What does Lisbon offer?
The programme's attraction is access: a working base in Portugal and a chance to build international relationships. For a Brazilian company looking toward Europe, Lisbon offers language and business connections, but those advantages do not eliminate regulatory, commercial or cultural differences.
A serious expansion plan would need to identify the target customer, expected procurement cycle, data handling, professional responsibilities and what evidence a potential buyer needs. A business can be successful at home and still require a different go-to-market approach abroad.

Is this the same as the Paraíba Spotlight deal?
No. Paraíba's separately reported agreement concerns a four-year Web Summit Spotlight initiative in João Pessoa. The Sebrae and ApexBrasil announcement concerns a cohort of 20 startups selected for an incubation cycle starting in Lisbon in March 2027. The partners, programme, location and timetable are different.
The next useful update will be what Agendart, MedHy and Odapp achieve during the programme: named partnerships, completed pilots or a commercially meaningful European foothold. The selection announcement opens the door. It doesn't tell us what happens after they walk through it.
Why the incubation announcement deserves attention
International startup programmes are often described in terms of exposure. Founders travel, attend a conference and meet possible partners. An incubation programme asks a more demanding question: what support can help a business turn that international interest into an operating presence in a new market?
The November 10 announcement at the Brazil pavilion involved Sebrae and ApexBrasil selecting 20 Brazilian startups for a Lisbon incubation cycle scheduled to begin in March 2027. The programme includes companies beyond healthcare, so it is best distinguished from a 20-company health-tech initiative. Three named health-related companies in the selection are Agendart, MedHy, also identified with Smart Healthy, and Odapp.
The date is significant. Selection occurred during Web Summit Lisbon 2026, while the actual incubation cycle was scheduled for the following year. Being chosen for the programme is a confirmed milestone. It does not mean the companies had already completed incubation, established European subsidiaries or secured customers at the time of the announcement.
The selection is nevertheless useful news. For health startups, structured time in another market can be more informative than a brief visit, provided the programme helps founders find relevant buyers and understand the operational realities of expansion.
What can an incubation programme solve?
A company entering a new country faces several simultaneous challenges. It needs to understand its customer, find credible local partners and decide how much of the existing product can be used without change. It also needs to understand legal obligations, pricing expectations and the cost of maintaining operations.
A well-designed incubation programme can help founders work through those questions with local expertise. Introductions to investors are useful, but connections to potential customers, clinicians, researchers and operational partners may be equally important for healthcare ventures.
The programme itself is not necessarily evidence of commercial success. Its value will depend on what the companies do during and after the cycle. A startup may discover that its initial market assumptions were wrong. That can still be a productive outcome if it leads to a more realistic strategy rather than a premature launch.
For public agencies supporting internationalisation, the strongest evidence of impact will come from follow-up. How many selected companies establish meaningful partnerships? Which begin formal evaluations or secure paying customers? What changes are made to products because of local feedback? Those are more informative measures than the number of founders who attend an opening event.
Why the three health startups need separate stories
Agendart, MedHy and Odapp are the three health-related names in a cohort spanning several sectors. Their selection gives them access to a programme scheduled to begin in Lisbon in March 2027.
A business supporting scheduling or care administration has different evidence and adoption requirements from one providing health measurements or clinical information.
For each selected startup, the intended user, product function and development stage shape its route to market. Clinical involvement and local workflow requirements are especially relevant when a product supports care.
It would also be useful to ask each team why Portugal is the intended entry point. A shared language with Brazil may help initial discussions, but the underlying healthcare systems, commercial structures and professional requirements are not interchangeable.

Portugal can be a gateway, but not a regulatory shortcut
Lisbon offers access to technology organisations, professional networks and European investors. For Brazilian founders, cultural familiarity and language can reduce some early barriers. But operating in Portugal does not automatically grant access to every European healthcare market.
The details depend on the product. Software that handles personal information needs an appropriate data-protection approach. A clinical service may involve professional regulation and local care pathways. A medical device may require conformity assessment and other steps depending on its intended use and classification. An incubator can help companies understand these requirements, but selection itself is not a regulatory authorisation.
Procurement also varies. A company that sells directly to individual consumers has a different path from one seeking contracts with public hospitals. A product designed for a private clinic may need substantial changes to work with national health-system workflows. Founders should enter the programme with specific use cases rather than a vague plan to sell across Europe.
The commercial case matters just as much. A Portuguese pilot should reveal who is willing to pay, what the buyer values and how the company can support customers after implementation. If a pilot depends on significant manual effort from the founding team, the business must determine whether that model can scale.
How this differs from Paraíba's Web Summit deal
Both stories involve Brazilian participation at Web Summit, but they describe different agreements. The Paraíba Spotlight deal was a four-year arrangement involving a Brazilian state and the conference, connected to a regional delegation. The Sebrae and ApexBrasil announcement selected a defined group of startups for a future Lisbon incubation cycle.
Combining them would create a misleading picture of one large initiative. They have different organisers, participants, purposes and timelines. A reader should be able to understand what each agreement actually provides without treating the entire Brazil pavilion as one programme.
The distinction also affects how outcomes should be measured. A multiyear conference presence may be assessed through recurring participation and business connections. An incubation programme may be assessed through what selected companies accomplish during a concentrated period of market work. Both can be useful if their objectives remain clear.
What to watch in March 2027
When the Lisbon cycle begins, participation, practical support and new customer or research relationships will become measures of progress. For the health-related teams, hospital connections, clinical partners and clearly defined evaluation milestones could be particularly valuable.
For Agendart, MedHy and Odapp, the most interesting evidence would be a documented use case and a credible local partnership or evaluation. It would also be valuable to understand whether each company changes its commercial model or product after meeting Portuguese buyers.
The November announcement is a meaningful selection event, not, by itself, evidence of European market traction. Its real significance lies in the possibility of moving beyond conference introductions toward structured, measurable international expansion. For a health startup, that transition is where the difficult and worthwhile work begins.












